by
Thomas Dworetzky, Contributing Reporter | December 23, 2016
Three of every four new participants will get the beta secretese-inhibiting agent, the other gets placebo. The candidates will be followed for four years or more to see if the drug slows or blocks the onset of the devastating condition.
“The DIAN-TU trials will provide a rigorous and powerful test of the amyloid hypothesis while evaluating a potential preventive treatment option for autosomal dominant Alzheimer’s disease,” said Dr. Gary Romano, who is head of Alzheimer’s Disease Development for Janssen Research & Development.
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The trial is also investigating gantenerumab, a Roche-developed antibody that affixes to amyloid beta clumps and furthers their removal from the brain, and the Eli Lilly agent solanezumab, also an antibody, but one that attaches itself to amyloid beta protein fragments that have yet to clump into plaques and are floating free.
“We are pleased to see the DIAN-TU trial researchers continuing to broaden the types of investigational drugs they are testing,” said Maria Carrillo, Ph.D., chief science officer of the Alzheimer’s Association, which is helping to fund the trial. “Alzheimer’s is a very complex disease, and it is extremely important that we develop therapies to address Alzheimer’s from a variety of angles and at multiple stages of the disease.”
Alzheimer’s research made news last month, when the Eli Lilly anti-Alzheimer's drug
"did not meet the primary endpoint” in its phase 3 clinical trial.
Lilly announced at that time that it would not pursue regulatory submissions for the agent's use in Alzheimer's.
"The results of the solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer's disease," John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, said in a statement. "We will evaluate the impact of these results on the development plans for solanezumab and our other Alzheimer's pipeline assets."
Back to HCB News
